QUADRATUS BIOFINANCE LIMITEDActive – proposal to strike off

Company number 07304900Private limited companyIncorporated 2010
⚠ Accounts overdue. The next accounts were due on 30 Apr 2026 and had not been filed when the register was last updated.
⚠ Confirmation statement overdue. It was due on 24 Apr 2026.
Company status at Companies House: Active - Proposal to Strike off.

Key figures

£1+0.0%
Net assets 2023/24
+0.0%
Average annual growth 2020/21–2023/24
00.30.50.812020/212021/222022/232023/24

Like most small UK companies, QUADRATUS BIOFINANCE LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
00.512020/212021/222022/232023/24
Filed accounts2020/21–2023/24
2020/212021/222022/232023/24
Cash at bank and in hand—1——
Total assets——1—
Total liabilities————
Net assets / total equity1111
Average number of employees0—0—

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: QUADRATUS BIOFINANCE LIMITED

Company

QUADRATUS BIOFINANCE LIMITED is a private limited company registered with Companies House under company number 07304900. It was incorporated on 5 Jul 2010. Its status is active – proposal to strike off. The registered office is in Cardiff (CF14). Its nature of business (SIC 2007) is other research and experimental development on natural sciences and engineering (72190).

Accounts

The latest accounts in the database are for 2023/24 (period ending 31 Jul 2024); the company files dormant company accounts. Net assets were £1, up 0% on the previous year. Figures are available for 4 financial years (2020/21–2023/24).

Control and charges

One person with significant control is registered.

Filing deadlines

The next accounts are due by 30 Apr 2026. The next confirmation statement is due by 24 Apr 2026.